Journal article
Worse stroke outcome in atrial fibrillation is explained by more severe hypoperfusion, infarct growth, and hemorrhagic transformation
HTH Tu, BCV Campbell, S Christensen, PM Desmond, DA De Silva, MW Parsons, L Churilov, MG Lansberg, M Mlynash, JM Olivot, M Straka, R Bammer, GW Albers, GA Donnan, SM Davis
International Journal of Stroke | Published : 2015
DOI: 10.1111/ijs.12007
Abstract
Atrial fibrillation is associated with greater baseline neurological impairment and worse outcomes following ischemic stroke. Previous studies suggest that greater volumes of more severe baseline hypoperfusion in patients with history of atrial fibrillation may explain this association. We further investigated this association by comparing patients with and without atrial fibrillation on initial examination following stroke using pooled multimodal magnetic resonance imaging and clinical data from the Echoplanar Imaging Thrombolytic Evaluation Trial and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution studies. Methods: Echoplanar Imaging Thrombolytic Evaluatio..
View full abstractGrants
Awarded by National Institute of Neurological Disorders and Stroke
Funding Acknowledgements
The EPITHET study was supported by the National Health and Medical Research Council of Australia (NHMRC), National Stroke Foundation (NSF), and National Heart Foundation of Australia (NHF). The DEFUSE study was funded by National Institutes of Health (NIH) Grants RO1 NS39325, Principal Investigator, Gregory W. Albers; K24 NS044848, Principal Investigator, Gregory W. Albers; K23 NS051372, Principal Investigator, Maarten G. Lansberg; and the RAPID software development was supported by R01 EB002711, Principal Investigator, Roland Bammer. Hans Tu is supported by the Royal Melbourne Hospital Neurosciences Foundation. Tissue plasminogen activator was supplied at no charge by Boehringer Ingelheim (Australian, New Zealand, and European sites) and Genentech (US and Canadian sites). Neither Boehringer Ingelheim, Genentech, NIH, NHMRC, NSF, NHF, nor the Royal Melbourne Hospital Neurosciences Foundation played a role in the design and the conduct of the studies; collection, management, analysis, and interpretation of the data; or preparation or approval of the manuscript.